PTN — Palatin Technologies, Inc. Common Stock
NASDAQ · Healthcare · Biotechnology
$11.54
+$1.55 (+15.52%)
Palatin Technologies, Inc. Common Stock (PTN) is a biotechnology company listed on NASDAQ. It is led by Carl Spana Ph.D., based in 11 Deer Park Drive, Monmouth Junction, NJ, United States, 08512, with about 29 employees. Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequately responsive to PDE5i monotherapy. The company also develops PL9643 for dry eye disease and anti-inflammatory ocular indications; and oral PL8177 for the treatment inflammatory bowel diseases. Palatin Technologies, Inc. was incorporated in 1986 and is based in Monmouth Junction, New Jersey.
Latest reported PTN revenue for 2025-09-30 was $8.8M. Net income was $4.7M. PTN currently screens at market cap $21.8M and trailing P/E 111.4.
Use this PTN page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the PTN quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the PTN SEC filings page. Lician reads the product cache first so this HTML stays unique to Palatin Technologies, Inc. Common Stock even when a live quote feed is slow.
About Palatin Technologies, Inc. Common Stock
Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequately responsive to PDE5i monotherapy. The company also develops PL9643 for dry eye disease and anti-inflammatory ocular indications; and oral PL8177 for the treatment inflammatory bowel diseases. Palatin Technologies, Inc. was incorporated in 1986 and is based in Monmouth Junction, New Jersey.
PTN Key Statistics
Market Cap
$21.80M
Volume
104,870
Previous Close
$10.16
Day Range
$9.88 – $10.92
P/E Ratio
111.36
P/B Ratio
2.06
EPS
-$32.15
Revenue
$0.00
Net Income
-$17.31M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
-100.0%
Employees
29
PTN Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $0.00 | $4.49M | $4.85M | $1.47M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$17.31M | -$29.74M | -$27.54M | -$36.20M |
| EPS (Diluted) | -$32.15 | -$101.16 | $0.00 | $0.00 |
Total Assets
$3.27M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$2.56M
Operating Cash Flow
-$21.31M
Free Cash Flow
$0.00
Palatin Technologies, Inc. Common Stock Company Information
- Co-Founder, President, CEO & Director
- Carl Spana Ph.D.
- Headquarters
- 11 Deer Park Drive, Monmouth Junction, NJ, United States, 08512
- Website
- palatin.com
- Phone
- 609 495 2200
- IPO / Founded
- 1993-10-28
- Sector
- Healthcare
- Industry
- Biotechnology